Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 216

1.

Oncogenes come of age.

Varmus H, Pao W, Politi K, Podsypanina K, Du YC.

Cold Spring Harb Symp Quant Biol. 2005;70:1-9. Review.

2.

Epidermal growth factor receptor mutations in lung cancer.

Sharma SV, Bell DW, Settleman J, Haber DA.

Nat Rev Cancer. 2007 Mar;7(3):169-81. Review.

PMID:
17318210
3.

Resistance to EGF-R (erbB-1) and VEGF-R modulating agents.

Dempke WC, Heinemann V.

Eur J Cancer. 2009 May;45(7):1117-28. doi: 10.1016/j.ejca.2008.11.038. Review.

PMID:
19124237
4.

Oncogene-blocking therapies: new insights from conditional mouse tumor models.

Hengstler JG, Bockamp EO, Hermes M, Brulport M, Bauer A, Schormann W, Schiffer IB, Hausherr C, Eshkind L, Antunes C, Franzen A, Krishnamurthi K, Lausch E, Lessig R, Chakrabarti T, Prawitt D, Zabel B, Spangenberg C.

Curr Cancer Drug Targets. 2006 Nov;6(7):603-12. Review.

PMID:
17100566
5.

[Recent progress in oncogene studies].

Toyoshima K.

Gan To Kagaku Ryoho. 1987 Jun;14(6 Pt 2):2135-9. Japanese.

PMID:
3606142
6.

Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.

Mounawar M, Mukeria A, Le Calvez F, Hung RJ, Renard H, Cortot A, Bollart C, Zaridze D, Brennan P, Boffetta P, Brambilla E, Hainaut P.

Cancer Res. 2007 Jun 15;67(12):5667-72.

7.

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.

Ladanyi M, Pao W.

Mod Pathol. 2008 May;21 Suppl 2:S16-22. doi: 10.1038/modpathol.3801018. Review.

8.

Cyclins and related kinases in cancer cells.

Malumbres M.

J BUON. 2007 Sep;12 Suppl 1:S45-52. Review.

PMID:
17935277
9.

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses.

Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, Stella GM, Lamba S, Cancelliere C, Russo M, Geuna M, Appendino G, Fantozzi R, Medico E, Bardelli A.

Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20864-9. doi: 10.1073/pnas.0808757105.

10.

Modeling cancer in mice.

Jackson-Grusby L.

Oncogene. 2002 Aug 12;21(35):5504-14. Review.

11.

The new era in cancer research.

Varmus H.

Science. 2006 May 26;312(5777):1162-5.

PMID:
16728627
12.

Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.

Wu CC, Hsu HY, Liu HP, Chang JW, Chen YT, Hsieh WY, Hsieh JJ, Hsieh MS, Chen YR, Huang SF.

Cancer. 2008 Dec 1;113(11):3199-208. doi: 10.1002/cncr.23925.

13.

Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.

Thomas RK, Greulich H, Yuza Y, Lee JC, Tengs T, Feng W, Chen TH, Nickerson E, Simons J, Egholm M, Rothberg JM, Sellers WR, Meyerson ML.

Cold Spring Harb Symp Quant Biol. 2005;70:73-81.

PMID:
16869740
14.

Technologically advanced cancer modeling in mice.

Tuveson DA, Jacks T.

Curr Opin Genet Dev. 2002 Feb;12(1):105-10. Review.

PMID:
11790563
15.

Targeting the AKT protein kinase for cancer chemoprevention.

Crowell JA, Steele VE, Fay JR.

Mol Cancer Ther. 2007 Aug;6(8):2139-48. Review.

16.

Molecular interrelationships in multidrug resistance (review).

Kellen JA.

Anticancer Res. 1994 Mar-Apr;14(2A):433-5. Review.

PMID:
8017843
17.
18.

Somatic pharmacogenomics in cancer.

Ikediobi ON.

Pharmacogenomics J. 2008 Oct;8(5):305-14. doi: 10.1038/tpj.2008.8. Review.

PMID:
18679398
19.

Molecular pathways in tumor progression: from discovery to functional understanding.

Ali MA, Sjöblom T.

Mol Biosyst. 2009 Sep;5(9):902-8. doi: 10.1039/b903502h. Review.

PMID:
19668850
20.

Oncogenes in human cancers and in chemically induced animal tumors.

Barbacid M.

Prog Med Virol. 1985;32:86-100. Review. No abstract available.

PMID:
3895300

Supplemental Content

Support Center